Suche klinische Studie
Weitere Suchoptionen
23 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; Studie unter Beteiligung von ERN-Mitgliedern aus mindestens zwei Mitgliedstaaten = 
Nationale klinische Studie(n)
BELGIEN
ANTWERPEN
EDEGEM (ANTWERPEN)
ATTRACT study: A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT - BE
Antwerp University Hospital - UZA
CEMA - Centrum voor Erfelijke Metabole Aandoeningen
BELGIEN
ANTWERPEN
EDEGEM (ANTWERPEN)
An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease (Phase III) - BE
Antwerp University Hospital - UZA
Department of pediatric metabolic diseases (Metabole stoornissen kinderen/Metabolic Disorders in Children)
DEUTSCHLAND
Bayern
OCHSENFURT
Eine doppelblinde, randomisierte, Placebo-kontrollierte Studie zur Untersuchung der Wirksamkeit, Sicherheit und Pharmakodynamik von AT1001 bei Patienten mit Fabry-Krankheit und einer GLA-Mutation, die auf AT1001 anspricht (Phase III)
Facharztpraxis für innere Medizin und Nephrologie
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
ATTRACT: Eine randomisierte offene Studie zum Vergleich der Wirksamkeit und Sicherheit von AT1001 und einer Enzymersatztherapie (EET) bei Patienten mit Fabry-Krankheit und einer GLA-Mutation, die auf AT1001 anspricht (Phase III)
Institution: Information not provided - DE
FRANKREICH
ILE-DE-FRANCE
GARCHES
A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease (Phase II) - Terminated -
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Génétique Médicale - Centre de référence Maladies Rares
FRANKREICH
ILE-DE-FRANCE
GARCHES
A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease (Phase II) - Terminated -
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Génétique Médicale - Centre de référence Maladies Rares
FRANKREICH
ILE-DE-FRANCE
GARCHES
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - FR
CHU Paris IdF Ouest - Hôpital Raymond Poincaré
Service de Génétique Médicale - Centre de référence Maladies Rares
NIEDERLANDE
Noord-Holland
AMSTERDAM
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations (Phase III) - NL
Amsterdam UMC
Afdeling Erfelijke Stofwisselingsziekten
NIEDERLANDE
Noord-Holland
AMSTERDAM
An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease
Amsterdam UMC
Afdeling Erfelijke Stofwisselingsziekten
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
ATTRACT: A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT (Phase 3) - AT
Institution: Information not provided - AT
POLEN
Warszawa
WARSAW
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - PL
Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego
Klinika Kardiologii i Angiologii Interwencyjnej
SPANIEN
Aragón
ZARAGOZA
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations - ES (completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPANIEN
Aragón
ZARAGOZA
An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease - ES (Completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPANIEN
Cataluña
BARCELONA
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations - ES (completed)
Fundació Puigvert
Servicio de Nefrología
SPANIEN
Cataluña
BARCELONA
An Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in subjects with Fabry Disease - ES (Completed)
Fundació Puigvert
Servicio de Nefrología
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An open-label study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of 12-month treatment with migalastat in pediatric subjects (aged 12 to <18 years) with fabry disease and amenable GLA variants - ES (completed)
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-Stage Renal Disease Treated With Hemodialysis -ES
Institution: Information not provided - ES
VEREINIGTES KONIGREICH
Greater London
LONDON
Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease (Phase II)
Royal Free Hospital
Lysosomal storage disorders unit, Dept. of Haematology
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT (phase III) - UK
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations (Phase III) - UK
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
SALFORD
FAB-CL-204: A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients With Fabry Disease
Hope Hospital, University of Manchester
Department of Metabolic Disease
VEREINIGTES KONIGREICH
Greater Manchester
SALFORD